Deflazacort for Type-1 Autoimmune Hepatitis in a Korean Girl.
10.3346/jkms.2006.21.4.758
- Author:
Sun Hwan BAE
1
;
Jae Seon KIM
;
Dong Hoon KIM
Author Information
1. Department of Pediatrics, School of Medicine, Konkuk University, Seoul, Korea. baedori@hanafos.com
- Publication Type:Case Report
- Keywords:
Hepatitis, Autoimmune;
deflazacort;
Child
- MeSH:
Ursodeoxycholic Acid/therapeutic use;
Treatment Outcome;
Pregnenediones/*therapeutic use;
Korea;
Immunosuppressive Agents/therapeutic use;
Humans;
Hepatitis, Autoimmune/*drug therapy;
Female;
Drug Therapy, Combination;
Cholagogues and Choleretics/therapeutic use;
Child
- From:Journal of Korean Medical Science
2006;21(4):758-760
- CountryRepublic of Korea
- Language:English
-
Abstract:
Prednisone or prednisolone are the mainstay drug treatments for autoimmune hepatitis in children. However, long-term use of corticosteroid is associated with the risk of steroid-induced toxicities, and this situation requires newer immuno-suppressive agents for the treatment of autoimmune hepatitis, especially in growing children. An 11-yr-old Korean girl with type-1 autoimmune hepatitis discontinued prednisolone due to toxicities, i.e., hirsutism, buffalo hump, and skin striae, and remained clinical and biochemical remission under replacement of deflazacort and ursodeoxycholic acid combination therapy. A follow-up liver biopsy after 19 months of deflazacort and ursodeoxycholic acid treatment showed histologic remission.
